Skip to main content
    C

    Cogent Biosciences Inc (COGT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $27.44
    -1.12 (-3.92%)

    Market Cap: $4.97B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Cogent Biosciences Inc (COGT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Cogent Biosciences reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$328.94M, operating cash flow was -$264.44M and free cash flow was -$266.00M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$111.43M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $333.36M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$7.87M-65.0%-227.0%-1044.3%-950.4%
    Dec 2019$22.50M+131.1%100.0%-143.0%-134.6%
    Dec 2018$9.73M+16.4%100.0%-369.9%-354.8%
    Dec 2017$8.36M+31.5%100.0%-312.8%-304.9%
    Dec 2016$6.36MN/A100.0%-300.1%-285.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$0$0$7.87M$22.50M$9.73M$8.36M$6.36M
    Cost of revenue$4.62M$4.40M$3.59M$5.88M$147.00K$25.74M$43.71KN/AN/AN/A
    Gross profit-$4.62M-$4.40M-$3.59M-$5.88M-$147.00K-$17.87M$22.50M$9.73M$8.36M$6.36M
    Research and development$269.78M$232.66M$173.75M$121.63M$55.91M$72.65M$43.71M$38.28M$29.83M$21.99M
    Operating income-$333.36M-$275.94M-$208.13M-$147.84M-$75.55M-$82.20M-$32.18M-$36.01M-$26.15M-$19.07M
    Net income-$328.94M-$255.86M-$192.41M-$132.64M-$72.27M-$74.81M-$30.27M-$34.53M-$25.49M-$18.12M
    EBITDA-$321.29M-$251.51M-$188.82M-$141.96M-$72.13M-$34.57M-$30.89M-$34.68M-$24.98M-$18.24M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$4.29M$0$0$0$5.59M
    Gross profitN/AN/A-$1.16M-$1.18MN/A-$1.16M-$1.14M$2.15M-$1.10M-$1.08M-$1.07M$4.79M
    Operating income-$117.18M-$102.64M-$103.61M-$99.49M-$83.36M-$75.58M-$74.93M-$73.73M-$75.41M-$64.39M-$62.40M-$58.23M
    Net income-$111.43M-$96.41M-$97.35M-$102.49M-$80.93M-$73.53M-$71.99M-$67.93M-$70.63M-$58.95M-$58.35M-$54.37M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $224.44M by $87.57M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$937.61M$327.90M$313.44M$300.81M$232.09M$250.92M$49.42M$85.93M$49.12M$75.55M
    Current assets$910.36M$296.47M$270.77M$264.97M$222.63M$244.91M$40.59M$81.00M$42.38M$69.73M
    Cash and equivalents$312.01M$98.17M$53.23M$139.89M$219.68M$242.19M$37.42M$55.67M$28.27M$41.32M
    Total liabilities$301.24M$71.61M$55.63M$45.08M$17.91M$16.25M$17.66M$25.69M$20.81M$23.16M
    Short-term debt$1.55M$1.56M$1.39M$1.42M$2.32M$2.05M$1.62M$3.80M$2.77M$1.20M
    Long-term debt$222.90MN/AN/AN/AN/AN/AN/AN/AN/AN/A
    Shareholder equity$636.37M$256.29M$257.80M$255.74M$214.18M$234.67M$31.76M$60.23M$28.30M$52.39M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$832.14M$834.55M$903.01M$937.61M$425.93M$274.82M$283.80M$327.90M$384.02M$429.94M$476.11M$313.44M
    Total liabilities$315.88M$302.16M$295.31M$301.24M$123.47M$119.78M$64.80M$71.61M$69.36M$56.71M$53.78M$55.63M
    Cash and equivalents$217.46M$181.17M$241.21M$312.01M$125.30M$127.60M$126.00M$98.17M$97.05M$88.22M$215.80M$53.23M
    Shareholder equity$516.26M$532.39M$607.69M$636.37M$302.46M$155.04M$219.00M$256.29M$314.66M$373.22M$422.33M$257.80M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$264.44M-$207.79M-$153.62M-$118.64M-$58.76M-$35.85M-$41.51M-$32.49M-$25.84M-$18.64M
    Capital expenditures$1.55M$573.00K$2.80M$6.86M$1.72M$320.00K$33.00K$549.00K$912.00K$3.31M
    Free cash flow-$266.00M-$208.36M-$156.42M-$125.50M-$60.48M-$36.17M-$41.55M-$33.04M-$26.75M-$21.95M
    Investing cash flow-$399.53M$38.28M-$97.82M-$124.72M-$1.72M$8.42M$23.16M-$10.53M$13.51M-$30.43M
    Financing cash flow$878.23M$214.45M$163.54M$163.56M$37.98M$232.20M$108.00K$70.35M-$729.00K-$40.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$80.79M-$77.27M-$86.88M-$79.11M-$64.29M-$54.54M-$66.51M-$60.58M-$51.98M-$42.70M-$52.53M-$44.07M
    Capital expenditures$108.00K$370.00K$449.00K$811.00K$65.00K$131.00K$547.00K$75.00K$280.00K$148.00K$70.00K$315.00K
    Free cash flow-$80.89M-$77.64M-$87.33M-$79.92M-$64.35M-$54.67M-$67.06M-$60.65M-$52.26M-$42.85M-$52.60M-$44.38M
    Last 12 quarters

    Frequently Asked Questions About COGT

    What is Cogent Biosciences' annual revenue?

    Cogent Biosciences reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Cogent Biosciences profitable?

    No. Cogent Biosciences reported net income of -$328.94M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does COGT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$264.44M minus capital expenditures of $1.55M produced free cash flow of -$266.00M.

    How much debt does Cogent Biosciences have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $222.90M, short-term debt of $1.55M and cash and equivalents of $312.01M.